Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 861

1.

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):373-9. Epub 2007 Oct 24.

PMID:
17919894
[PubMed - indexed for MEDLINE]
2.
3.

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Diabetes Technol Ther. 2007 Aug;9(4):387-98.

PMID:
17705695
[PubMed - indexed for MEDLINE]
4.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.

PMID:
14693980
[PubMed - indexed for MEDLINE]
5.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
[PubMed - indexed for MEDLINE]
6.

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.

PMID:
15889234
[PubMed - indexed for MEDLINE]
7.

[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].

Rodríguez A, Reviriego J, Polavieja P, Mesa J.

Med Clin (Barc). 2008 Nov 29;131(19):721-30. Spanish.

PMID:
19091199
[PubMed - indexed for MEDLINE]
8.

Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.

Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.

J Indian Med Assoc. 2008 Jul;106(7):464-7.

PMID:
18975505
[PubMed - indexed for MEDLINE]
9.

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.

Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT.

Drugs Aging. 2004;21(4):259-71.

PMID:
15012171
[PubMed - indexed for MEDLINE]
10.

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.

Diabetes Care. 2004 Jan;27(1):41-6.

PMID:
14693964
[PubMed - indexed for MEDLINE]
11.

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

Clin Ther. 2000 Dec;22(12):1395-409.

PMID:
11192132
[PubMed - indexed for MEDLINE]
12.

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.

PMID:
17026489
[PubMed - indexed for MEDLINE]
13.

Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.

Khan M, Xu Y, Edwards G, Urquhart R, Mariz S.

Int J Clin Pract. 2004 Oct;58(10):907-12.

PMID:
15587767
[PubMed - indexed for MEDLINE]
14.

Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials.

Rajagopalan R, Iyer S, Khan M.

Curr Med Res Opin. 2005 Jan;21(1):163-72.

PMID:
15881488
[PubMed - indexed for MEDLINE]
15.

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN.

Diabet Med. 2000 Jan;17(1):40-7.

PMID:
10691158
[PubMed - indexed for MEDLINE]
16.
17.
18.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Hermann LS, Ranstam J, Vaaler S, Melander A.

Diabetes Obes Metab. 1999 Jul;1(4):227-32.

PMID:
11228758
[PubMed - indexed for MEDLINE]
19.

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, Charbonnel B; PROactive investigators.

Diabet Med. 2009 Dec;26(12):1242-9. doi: 10.1111/j.1464-5491.2009.02857.x.

PMID:
20002476
[PubMed - indexed for MEDLINE]
20.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk